Evidence map›Paper›PMID 37337181›Full record

ArticleBMC public health2023

Pay-it-forward gonorrhea and chlamydia testing among men who have sex with men and male STD patients in China: the PIONEER pragmatic, cluster randomized controlled trial protocol.

Gifty Marley, Rayner Kay Jin Tan, Dan Wu, Tong Wang, Murong Sun, Qilei Sheng, Margaret Elizabeth Holly, Takhona Grace Hlatshwako, Cheng Wang, Weiming Tang and 8 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05723263 (IGHID 12118 - Pay-it-forward Gonorrhea and Chlamydia Testing Among Men in China), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05723263 nacompletednot on this map

IGHID 12118 - Pay-it-forward Gonorrhea and Chlamydia Testing Among Men in China: The PIONEER Pragmatic Randomized Controlled Trial

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2023 to 2024Enrolled1,200ConditionsGonorrhea, ChlamydiaArmsStandard Pay-it-forward, Community Engaged Pay-it-forward, Control arm
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Gifty Marley *University of North Carolina Project-China, Guangzhou, China.
Rayner Kay Jin TanUniversity of North Carolina Project-China, Guangzhou, China.
Dan Wu *Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.
Tong WangUniversity of North Carolina Project-China, Guangzhou, China.
Murong SunUniversity of North Carolina Project-China, Guangzhou, China.
Qilei ShengUniversity of North Carolina Project-China, Guangzhou, China.
Margaret Elizabeth HollyUniversity of North Carolina at Chapel-Hill, Chapel Hill, NC, USA.
Takhona Grace HlatshwakoUniversity of North Carolina at Chapel-Hill, Chapel Hill, NC, USA.
Cheng WangDermatology Hospital, Southern Medical University, Guangzhou, China.
Weiming TangDepartment of Medicine, University of North Carolina at Chapel-Hill, Chapel Hill, NC, USA.
Rohit RamaswamyCincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Ligang YangDermatology Hospital, Southern Medical University, Guangzhou, China.
Danyang LuoUniversity of North Carolina Project-China, Guangzhou, China.
Sean S SylviaDepartment of Medicine, University of North Carolina at Chapel-Hill, Chapel Hill, NC, USA.
Kurt GrayUniversity of North Carolina at Chapel-Hill, Chapel Hill, NC, USA.
David Van DuinUniversity of North Carolina at Chapel-Hill, Chapel Hill, NC, USA.
Heping ZhengDermatology Hospital, Southern Medical University, Guangzhou, China.
Joseph D TuckerClinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. jdtucker@med.unc.edu.ORCID 0000-0003-2804-1181
University of North Carolina at Chapel Hill · USGuangzhou University · CNSouthern Medical University · CNCincinnati Children's Hospital Medical Center · USLondon School of Hygiene & Tropical Medicine · GB

Funding

Pay-it-forward gonorrhea testing among men who have sex with men: The PIONEER pragmatic randomized controlled trialR01AI158826 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TANG, WEIMING, TUCKER, JOSEPH DAVID · 2021 to 2025
$3.1M
Mentoring Multidisciplinary Global HIV Patient-Oriented ResearchK24AI143471 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph David Tucker · 2019 to 2026
$1.4M
Enhancing Partner Services among Men Who Have Sex with Men Living With HIV: A Pilot Randomized Controlled TrialR34MH119963 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TANG, WEIMING, TUCKER, JOSEPH DAVID · 2019 to 2021
$568k
NIAID NIH HHS K24 AI143471NIAID NIH HHS R01 AI158826NIMH NIH HHS R34 MH119963
6 · The paper itself

Abstract

backgroundGonorrhea and chlamydia are the most common sexually transmitted diseases (STDs) among men who have sex with men (MSM) in China. Previous studies have shown pay-it-forward (PIF) interventions to be associated with a substantial increase in gonorrhea and chlamydia test uptake compared to standard-of-care. We propose a 'pay-it-forward' gonorrhea and chlamydia testing randomized controlled trial (PIONEER). The trial would evaluate the effectiveness of two pay-it-forward strategies in promoting testing uptake compared to the standard of care (in which men pay for their tests out-of-pocket) among MSM and male STD patients in China.

methodsPIONEER will be a three-armed, pragmatic cluster randomized controlled trial (RCT), conducted across 12 clinics (six MSM-led and six public STD clinics) to compare the effectiveness of three implementation strategies. Each facility will be randomized to a standard pay-it-forward intervention of gonorrhea/ chlamydia testing with minimal encouragement for testing, a community-engaged pay-it-forward arm, or a control arm where men pay for their tests out-of-pockets. The primary outcome will be dual gonorrhea/chlamydia test uptake. Secondary outcomes will include syphilis testing, amount donated in pay-it-forward, number of positive gonorrhea and chlamydia tests, and measures of antimicrobial resistance. A sequential transformative mixed methods design will be used to evaluate the implementation process in type 2 effectiveness-implementation hybrid design. Data sources will include survey on acceptability, and feelings and attitudes towards the interventions among participants; testing and treatment uptake data from clinic records, WeChat records, and qualitative data to gain insights into men's perceptions and attitudes towards the pay-it-forward, mechanisms driving uptake, and donating behaviors. Implementers and organizers will be interviewed about fidelity and adherence to protocol, sustainability of pay-it-forward intervention, and barriers and facilitators of implementing the intervention. DISCUSSION: PIONEER will substantially increase gonorrhea/chlamydia testing among MSM in China, providing an innovative and new financial mechanism to sustain STD screening among sexual minorities in low- and middle-income countries. This study will answer compelling scientific questions about how best to implement pay-it-forward and the individual and organizational characteristics that moderate it.

trial registrationThe study with identification number NCT05723263 has been registered on clinicaltrials.gov/.

Indexed as

ChlamydiaChlamydia InfectionsGonorrheaHIV InfectionsSexual and Gender MinoritiesSexually Transmitted DiseasesChinaHomosexuality, MaleHumansMalePragmatic Clinical Trials as TopicRandomized Controlled Trials as TopicChlamydiaGonorrheaPay-it-forwardSocial innovationUpstream reciprocityWarm-glow

Identifiers

PMID37337181
PMCPMC10280958
OpenAlexW4381250243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.